Trial Profile
A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Genentech
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Planned End Date changed from 1 Sep 2013 to 26 Mar 2019.
- 16 Apr 2018 According to the Genentech media release, data from this study will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.